Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease.

NORRIS, Karl <http://orcid.org/0000-0001-5583-8298>, HODGSON, Rachel, DORNELLES, Tawni, ALLEN, K Elizabeth, ABELL, Benjamin <http://orcid.org/0000-0002-0953-0046>, ASHE, Mark P and CAMPBELL, Susan G <http://orcid.org/0000-0002-6740-1445>

Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/27871/

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version

NORRIS, Karl, HODGSON, Rachel, DORNELLES, Tawni, ALLEN, K Elizabeth, ABELL, Benjamin, ASHE, Mark P and CAMPBELL, Susan G (2020). Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease. Journal of Biological Chemistry.

Copyright and re-use policy

See http://shura.shu.ac.uk/information.html
Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease

Karl Norris¹,#, Rachel E. Hodgson¹, Tawni Dornelles², K. Elizabeth Allen¹, Ben M. Abell¹, Mark P. Ashe² and Susan G. Campbell¹*.

¹Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK. ²Division of Molecular and Cellular Function, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT UK.

#Present Address: School of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT UK

` both authors contributed equally to this work.

* To whom correspondence should be addressed: Susan G. Campbell, Biomolecular Sciences Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK; E-mail: susan.campbell@shu.ac.uk

Running title: eIF2Bα contributes to the formation of eIF2B bodies

Keywords: eIF2B, eIF2, translation initiation, VWM
ABSTRACT
Eukaryotic initiation factor 2B (eIF2B) serves as a vital control point within protein synthesis and regulates translation initiation in response to cellular stress. Mutations within eIF2B result in the fatal disease, leukoencephalopathy with vanishing white matter (VWM). Previous biochemical studies on VWM mutations have illustrated that changes in the activity of eIF2B poorly correlates with disease severity. This suggests that there may be additional characteristics of eIF2B contributing to VWM pathogenesis. Here, we investigated whether the localisation of eIF2B to eIF2B bodies was integral for function and whether this localisation could provide insight into the pathogenesis of VWM. We demonstrate that the regulatory subunit, eIF2Bα, is required for the assembly of eIF2B bodies in yeast and that loss of eIF2B bodies correlates with an inability of cells to regulate eIF2B activity. Mutational analysis of eIF2Bα showed that missense mutations which disrupt the regulation of eIF2B similarly disrupt the assembly of eIF2B bodies. In contrast, when eIF2Bα mutations which impact the catalytic activity of eIF2B were analysed, eIF2B bodies were absent and instead eIF2B localised to small foci, termed microfoci. FRAP analysis highlighted that within these microfoci, eIF2 shuttles more slowly indicating that formation of eIF2B bodies correlates with full eIF2B activity. When eIF2Bα VWM mutations were analysed a diverse impact on localisation was observed, which did not seem to correlate with eIF2B activity. These findings provide key insights into how the eIF2B body assembles and suggest that the body is a fundamental part of the translational regulation via eIF2α phosphorylation.

INTRODUCTION
Eukaryotic genomes encode many thousands of proteins and through the process of protein synthesis from mRNA or translation, the cell can rapidly control its gene expression profile to promote cellular homeostasis. The initiation step of translation is rate limiting and therefore provides a critical control point in gene expression. The highly conserved heterotrimeric G-protein, eukaryotic initiation factor 2 (eIF2), is essential for the initiation and regulation of translation. In its active GTP bound form, eIF2 binds to a methionyl initiator transfer RNA (Met-tRNAi) molecule to form a ternary complex (TC) (1). Facilitated by a number of eIFs, the TC is loaded onto the 40S ribosomal subunit and is recruited to a target mRNA molecule, allowing for subsequent ribosomal scanning and start codon recognition (1). Upon start codon recognition, eIF2-GTP is hydrolysed by the GTPase-activating protein, eIF5 (2) and is released from the ribosome in its inactive GDP bound form, in complex with eIF5 (1). For subsequent rounds of translation to occur within the cell, active eIF2-GTP must be replenished. eIF2 has a higher affinity for GDP than GTP (3) and therefore the multisubunit protein eIF2B is required to catalyse this guanine nucleotide exchange (4). In yeast, eIF5 functions as a GDP dissociation inhibitor (GDI), preventing any spontaneous recycling of GDP to GTP on eIF2 (5). In addition to its role as a guanine nucleotide exchange factor (GEF), in yeast eIF2B also acts as a GDI displacement factor (GDF), releasing eIF2-GDP from eIF5 (6).

Although functionally similar to other guanine nucleotide exchange factors of the ras superfamily, eIF2B has a much more complex quaternary structure. It is composed of five nonidentical subunits termed, α, β, δ, γ and ε, encoded in yeast by the genes: GCN3, GCD7, GCD2, GCD1 and GCD6, respectively. The native form of eIF2B is composed of a dimer of heteropentamers and so is decameric (7, 8). eIF2Bγ-eIF2Bε heterodimers reside on both flanks of the structure and are responsible for the protein’s GEF activity (4). Heterodimers of eIF2Bβ and δ subunits bind eIF2Bγε heterodimers and reside in the core of the decameric arrangement, stabilised in this conformation by an eIF2Bα homodimer. Structural analysis of both yeast and mammalian eIF2B has provided models for how the decameric structure is formed and how eIF2 can interact with the decamer (9-13). In mammalian cells, Wortham et al. identified that all eIF2B subunits, except eIF2Bα, are stoichiometrically regulated (14). Stable expression of eIF2Bε relies on similar levels of γ to be co-expressed; correspondingly eIF2Bβ requires similar levels of eIF2Bγε and β. Any surplus protein subunits are degraded by the ubiquitin-proteasome system.
This study indicated that the eIF2B holocomplex may be built around the eIF2Bεγβδ subcomplex, with eIF2Bα homodimers bridging two tetramers to complete the decameric holocomplex. In line with this model, Tsai et al., demonstrated that in the absence of eIF2Bα, eIF2B exists as an eIF2Bεγβδ tetramer (15).

The subunit complexity of eIF2B lends itself as a target of tight regulation. As the process of translation involves a significant amount of cellular energy, tight regulation is crucial in response to adverse cellular conditions. One of the best studied and most diverse mechanisms of translational control in response to cellular stress is the integrated stress response (ISR), known as the general amino acid control (GAAC) pathway in yeast (16, 17). The ISR involves a series of cellular stress sensing pathways that regulate translation through the common mechanism of eIF2 phosphorylation (18). In mammalian cells, four eIF2α kinases exist, whereas in yeast a single kinase, Gcn2p (general control nonderepressible 2), is responsible for the phosphorylation of eIF2α at serine 51 in response to amino acid starvation (19). Phosphorylation of eIF2α at this site converts eIF2 from a substrate to an inhibitor of eIF2B GEF activity. While the α, β and δ subunits of eIF2B are dispensable for GEF activity, they are responsible for tight regulation of this activity by phosphorylated eIF2 (20, 21). The inhibition of eIF2B GEF activity induces global translational repression within the cell. Paradoxically, a number of stress-responsive proteins are translationally upregulated to favour homeostatic reprogramming (18). The translation of these proteins is most commonly controlled by the presence of upstream open reading frames (uORFs) in the 5'UTR of the mRNAs, first demonstrated in yeast for GCN4 mRNA (22).

Recent structural studies in both yeast and mammalian systems have solved structures of eIF2B bound to both phosphorylated and non-phosphorylated eIF2α, (9-13, 23). Interestingly, although the structure of eIF2B is highly conserved across species (9, 10, 13), phosphorylated eIF2α appears to interact and inhibit eIF2B via distinct mechanisms within yeast and mammalian cells. While in mammalian cells, phosphorylated and non-phosphorylated eIF2α bind to different regions of eIF2B, in yeast, they share a binding pocket (10). eIF2α binds to the eIF2B regulatory subunits and this binding position is favourable for nucleotide exchange. Upon phosphorylation of eIF2α, conformational changes in its structure are believed to enhance the binding of eIF2α to eIF2Bα and δ subunits. It is this conformational change in eIF2B that displaces the catalytic domain of eIF2Bε, responsible for carrying out nucleotide exchange, from its original close proximity to eIF2 thus inhibiting nucleotide exchange (10).

Localisation studies in both yeast and mammalian systems have shown that eIF2B accumulates at specific foci within the cytoplasm of the cell (24-31). These foci have been termed eIF2B bodies and in yeast appear as one large cytoplasmic granule that morphologically exists as a filamentous-like structure. eIF2 also localises to eIF2B bodies raising the possibility that eIF2B bodies are sites where eIF2B GEF activity occurs and is regulated within the cell. In 2005, Campbell et al., demonstrated that in S. cerevisiae eIF2B is a stable component of eIF2B bodies, whereas the association of eIF2 is dynamic, with eIF2 transiting through the eIF2B body at a rate that correlates to the cellular level of eIF2B GEF activity (24). In 2010, Taylor et al observed that eIF2B bodies were motile throughout the cytoplasm (26). This movement is important for effective translation initiation as butanol treatment hinders eIF2B body movement and this lack of movement correlates with the inhibition of translation initiation. These data provide evidence to suggest eIF2B bodies are sites of eIF2B GEF activity and regulation, however recent interest in eIF2B bodies has provided some conflicting interpretations. One study has suggested that eIF2B bodies are not present in S. cerevisiae under steady-state growth, but only form under glucose limiting conditions (28). Interestingly, another study highlighted that eIF2B bodies were not induced during acute glucose starvation but were formed upon energy depletion (during stationary phase) as a mechanism for sequestering eIF2B proteins to inhibit their function (30, 31). Therefore, the significance of eIF2B assembly into eIF2B bodies for its function and regulation remains unclear.
The importance of understanding eIF2B localisation is heightened by the fact that in mammalian cells, mutations within eIF2B result in the fatal, autosomal recessive disease, leukoencephalopathy with vanishing white matter (VWM) (32). To date, over 200 VWM mutants have been identified spanning all five subunits (33). The relationship between mutant eIF2B function and disease severity remains poor. VWM causing mutations have been identified that affect neither decameric complex formation nor eIF2B activity in vitro but cause some of the most severe forms of VWM in vivo (34, 35). Understanding eIF2B body formation and regulation could uncover common pathophysiological mechanisms across the broad spectrum of causative mutations. Although GCN3, which encodes eIF2Bα, is the only nonessential eIF2B gene in yeast, it is still critical for stabilising eIF2B in its decameric conformation and for the regulation of eIF2B activity during cellular stress. Here we investigate the importance of eIF2Bα to eIF2B body assembly and activity. Using S. cerevisiae, we show that eIF2Bα (Gcn3p in S. cerevisiae) is central to the formation of eIF2B bodies and suggest that eIF2B bodies are a fundamental part of the translational regulation via eIF2α phosphorylation. Additionally, VWM causative mutations disrupt eIF2B body formation and regulation, providing the first evidence that eIF2B localisation is altered by VWM causing mutations.

RESULTS

eIF2B localisation varies between different yeast strains

Using C-terminally yeGFP tagged eIF2B subunits we have previously shown that, during steady state growth, all five subunits of eIF2B co-localise to eIF2B bodies (24-27). Recently, a number of groups have presented conflicting data about whether these eIF2B bodies exist during steady state growth or only form under specific starvation conditions (28, 30, 31). A potential explanation for these conflicting results is that different GFP tags may be influencing the aggregation of eIF2B. In order to investigate this, we first observed eIF2B body formation by individually tagging each eIF2B subunit with GFP and determining the percentage of cells in which eIF2B bodies were present. We hypothesized that if the eIF2B bodies that we have observed during steady state growth were due to aggregation of the GFP tag, we would expect to observe a similar percentage of cells containing eIF2B bodies for all 5 GFP tagged eIF2B subunits. While a similar percentage of cells contained eIF2B bodies when the eIF2Byγ (48 %), ε (51 %) and β (56 %) subunits were tagged, a lower percentage of cells contained eIF2B bodies when eIF2Bα (20 %) or δ (30 %) subunits where tagged (Figure 1A). These results suggest that it is unlikely that the GFP tag we have used is responsible for eIF2B body formation, rather, the ability of eIF2B to form bodies is influenced by the subunit that is tagged. Another possible explanation for differences in eIF2B body formation is variation between yeast strains, which are known to have differing responses to environmental stresses (36). In our previous studies, we have utilised S. cerevisiae W303-1A strain, while others have characterised eIF2B bodies in the BY4741 strain. To determine whether various lab strains localise eIF2B differently, the eIF2Byγ subunit was C-terminally GFP-tagged in the auxotrophic W303-1A, BY4741 and S288c background strains and eIF2B localisation was assessed. There was no difference in growth between strains (Fig S1). During steady state growth, a similar number of cells showing eIF2B bodies was observed for the W303-1A and S288c backgrounds (52 % and 50 % respectively), while a significantly lower number of cells were observed to show eIF2B bodies in the BY4741 strain background (11 %). To determine whether there was any change in the localisation upon stress, the cells were subjected to acute glucose starvation (30 min) and amino acid starvation (15 min). Previously, we had observed that the level of fluorescence within eIF2B bodies increased upon amino acid starvation and that this was dependent on the phosphorylation of eIF2α (24). Interestingly, upon amino acid starvation an increase in the number of cells showing eIF2B bodies was observed for all strains (Figure 1B). Whilst for the W303-1A and the S288c strains this increased percentage resulted in a 1.2-fold increase of cells with eIF2B bodies, for the BY4741 strain this
increased percentage of cells represents a much greater 2.3 fold increase. In contrast to these increases, following glucose starvation, the number of cells displaying eIF2B bodies slightly decreased for all strains W303-1A, eIF2Bγ-GFP (46%), S288c, eIF2Bγ-GFP (37%) and BY4741 eIF2Bγ-GFP (6%) however compared to SCD these differences were not found to be statistically significant. These results are consistent with data showing that eIF2B is not directly involved in translational control following glucose starvation (37-39). Overall, these results suggest that under normal growth, the level of eIF2B localisation to bodies depends on the *S. cerevisiae* strain, but that the trends in terms of responses to nutritional stress are similar and are dependent on stresses which target eIF2B activity.

**Deletion of eIF2Bα disperses eIF2B bodies**

In our previous studies we have shown that strains harbouring *gcn3* point mutations show no eIF2B bodies (26). eIF2Bα (Gen3p in yeast) is essential for decameric formation and therefore this phenotype could reflect destabilisation of the decameric complex. eIF2Bα is dispensable for eIF2B GEF activity but is required to regulate this activity in response to cellular stress. Within the eIF2B decameric complex, the eIF2Bα homodimer forms part of the regulatory core, which after cellular stress forms a high affinity interaction with phosphorylated eIF2 to prevent GDP to GTP exchange on non-phosphorylated eIF2 within the cell (23). Strains deleted for the eIF2Bα gene are viable in yeast under steady state conditions, however they cannot survive ISR activating stress conditions (18). To test whether eIF2B bodies form when it is no longer possible to stabilise the decameric complex, eIF2Bα (Gen3p in yeast) was deleted in strains harbouring either C-terminally GFP tagged eIF2Bγ (Gcd1p in yeast) or eIF2α (Sui2p in yeast). Upon deletion of the eIF2Bα gene, eIF2B does not localise to eIF2B bodies and instead is found completely dispersed throughout the cytoplasm as visualised using either eIF2Bγ-GFP and eIF2α-GFP strains (Figure 2A). The lack of response to conditions causing eIF2α phosphorylation in the *gcn3* null strain was also confirmed via polysome profiling (Figure S2A). Localisation of eIF2B to eIF2B bodies was rescued when eIF2Bα (Gen3p) was exogenously expressed on either a low copy centromeric or a high copy 2 micron plasmid (Figure 2A and Figure S2). Interestingly, a slight decrease in the number of cells showing eIF2B bodies was observed when eIF2Bα was over-expressed (50 % ± 9.0% versus 37 % ± 1.2%) (Fig 2B). Intriguingly, in addition to eIF2B bodies, for all strains except the *gcn3* null strain, eIF2B also localised to multiple smaller, punctate foci, which we termed microfoci however during steady state growth such microfoci were a rarely observed (Figure 2B).

These results show that eIF2Bα is required for the localisation of eIF2B to eIF2B bodies and are suggestive that the complete decameric complex may be required for eIF2B body assembly.

**Mutations in eIF2Bα alter the localisation of eIF2B**

To further investigate the role of eIF2Bα in the localisation of eIF2B and to determine whether eIF2B bodies have a functional role in regulating eIF2B activity, a series of well-characterised Gcn3p mutants were examined (Figure 3) (40). These mutations confer two distinct phenotypes that affect either the regulatory (Gcn-) or catalytic (Gcd-) activity of eIF2B. Genµ mutations prevent eIF2B activity from responding to cellular stress by impeding eIF2B-eIF2α-P interactions therefore allowing cells to continue eIF2B exchange activity even in the presence of phosphorylated eIF2α (Figure S3A). Gcdµ mutations reduce eIF2B GEF activity, which constitutively induces the expression of the stress responsive transcription factor Gcn4p (Figure S3B).

Eight Genµ and seven Gcdµ Gcn3p mutants were analysed for their impact on eIF2B body formation. The position of these mutations within the structure of Gcn3p can be seen in Figure 3. For all mutants analysed, eIF2B body formation was affected (Figure 4A). Interestingly, for the regulatory mutants (Genµ), no eIF2B bodies were observed, with the exception of the Gcn3 (S293R) mutant, where a small proportion of cells showed eIF2B bodies (6.7%) (Figure 4Ai and B). This loss of eIF2B bodies was not due to a decrease in protein...
expression (Figure S2B). This dispersal of the eIF2B body localisation observed in the Gcn3p regulatory mutants resembles the dispersal of eIF2B bodies in the gcn3 null strain and therefore seems likely to reflect the inability of these mutants to regulate eIF2B GEF activity rather than any change in subunit levels (Figure 2A).

While the regulatory mutants dispersed the localisation of eIF2B completely, the catalytic mutants resulted in the localisation of eIF2B to multiple smaller, punctate foci, termed microfoci (Figure 4Aii). These mutants also resulted in moderate reductions of subunit expression (Figure S2B). The only exception within this group of catalytic mutations was the AA6303//305Δ mutant where similar numbers of cells either dispersed eIF2B (33.5 %), formed microfoci (38.3 %) or formed eIF2B bodies (28.2 %) (Figure 4B).

**FRAP analysis identifies slower exchange within the microfoci**

Using, fluorescence recovery after photobleaching (FRAP) analysis we have previously demonstrated that the GEF activity of eIF2B is controlled and regulated in eIF2B bodies, as the rate of shuttling of eIF2 through eIF2B bodies was perturbed when phosphorylated eIF2α was present (24, 26). Since the eIF2Bα catalytic mutants display a Gcd- phenotype as assessed by their increased Gcn4p levels during steady state (Figure S3B), we postulated that disruption of the large eIF2B body to give microfoci (Figure 4Aii) may decrease the shuttling of eIF2 through eIF2B. To test this hypothesis, FRAP analysis was carried out on the AA25,26VV, E199K and AA303//305Δ mutant strains. As the mutant AA303//305Δ also formed eIF2B bodies as well as microfoci, this catalytic mutant represented a unique opportunity to investigate differences in the shuttling of eIF2 between the two types of eIF2B localisation in a single cell.

Fluorescence recovery of eIF2α-GFP was measured over time and mean recovery curves are shown in Figure 5B. Representative images across the different stages of the FRAP experiment are shown in Figure S4. Although the percentage of mobile eIF2 did not deviate significantly between the wild-type and any of the catalytic mutants (Figure 5Ci), the rate of eIF2 recovery into eIF2B bodies after photobleaching was consistently slower in the catalytic mutants than in wild-type cells (Figure 5Ciii). This is consistent with our previous analysis, where we showed a similar decreased rate of eIF2 shuttling for catalytic mutants in eIF2Bα (24). Consistent with this decreased rate, the AA25,26VV and E199K mutants exhibited increased half-time for eIF2 recovery in comparison to plasmid-borne wild-type GCN3 control (Figure 5Cii). Intriguingly, eIF2B shuttling through eIF2B bodies within the AA303//305Δ control was comparable to wild-type while, eIF2B shuttling through microfoci within this same mutant declined similarly to the other microfoci forming mutants AA25,25VV and E199K (Figure 5). Therefore, FRAP analyses of eIF2 suggest that the formation of eIF2B bodies enhances the eIF2 shuttling capacity relative to eIF2B microfoci.

**VWM mutations in the α subunit of eIF2B result in altered eIF2B localisation**

Mutations within eIF2B result in the fatal disease leukoencephalopathy with vanishing white matter (VWM). Previous biochemical studies on VWM mutations have relied upon in vitro analysis of eIF2B activity, complex integrity, and protein stability (33). While these analyses have illustrated that VWM mutations can impact the activity of eIF2B, the scale of observed effects correlates poorly with disease severity (34). Given the results from our localisation studies for mutations that differentially impact the regulatory or catalytic activity of eIF2B, it is possible that VWM mutations may also affect the integrity and GEF activity of eIF2B bodies; providing mechanistic insights into VWM pathophysiology. VWM causative mutations have been characterised in all 5 subunits of eIF2B, with 8 mutations identified in eIF2Bα (32, 33, 41, 42).

Of the 8 mutations identified in eIF2Bα, 1 results in a frameshift, 1 results in a deletion and 6 are missense mutations. Of the six missense mutated residues, only one is not conserved in yeast,
P278R (Q277 in yeast). Therefore, five VWM missense mutations K111E, N209Y, V184D, F240V and Y274C were investigated (Figure 6). While these mutations cause a range of disease severities in humans, no change in yeast cell growth was observed (Fig S5A). To determine what impact the VWM mutants had on the control of translation initiation, exponential cultures of the various strains were subjected to amino acid starvation and polysome profiling was performed (Figure 7A). In line with previous work, N209Y was identified as a Gcn' mutation and was unable to respond to stress (43). While the VWM mutation F240V displayed a similar phenotype to N209Y, the remaining mutants, V184D, K111E and Y274C, were all able to respond to amino acid starvation in a similar manner to the control strain (Figure 7A). We next determined whether these VWM eIF2Bα mutations had any impact on the localisation of eIF2B to eIF2B bodies. We hypothesised that if the mutations N209Y and F240V had Gcn' phenotypes that caused a disruption to the regulatory role of Gcn3p then eIF2B bodies would be dispersed throughout the cytoplasm. This was the case when eIF2B localisation was observed in the presence of the eIF2Bα N209Y mutation, (Figure 7B). In contrast, for the eIF2Bα F240V mutant strain, which displayed a Gcn' phenotype and could not respond to amino acid starvation, eIF2B bodies were partially disrupted with a decreased percentage of cells displaying them (13 %), (Figure 7B). The three mutations which do not affect the regulatory function of eIF2Bα, either decreased the number of cells displaying eIF2B bodies (K111E (29 %) and Y274C (20 %)) or in the case of the V184D mutant formed microfoci (Figure 7B). Surprisingly, these mutations did not show decreased eIF2B activity as measured by induced Gcn4 expression (Figure S5B).

We next made use of our FRAP assay to determine if these mutants impacted upon the ability of eIF2α to shuttle through eIF2B bodies. Intriguingly, although eIF2B bodies were present within the mutants V184D and F240V, eIF2α-GFP did not localise to discrete cytoplasmic bodies in these mutants and instead was dispersed throughout the cytoplasm (Figure S5D). Therefore, an analysis of eIF2 shuttling was not possible in these mutants and the lack of colocalization of eIF2 and eIF2B may reflect differences in affinities of these complexes.

In contrast, for the K111E and Y274C mutants, eIF2α-GFP did localise to eIF2B bodies and so, FRAP analysis was carried out to determine the impact of these mutations on the rate of eIF2 shuttling. One-phase association curves representing the recovery of eIF2 within eIF2B foci are shown in Figure 8A while representative images from the various stages of FRAP are displayed in Supp Figure 5E. In the presence of the K111E mutation, mobile eIF2 increased by 12% (Figure 8B) and the T1/2 recovery of eIF2 increased by 2.9 seconds, consistent with a decreased rate of recovery (Figure 8C). Similarly, in the presence of the Y274C mutation, mobile eIF2 increased by 24.6% (Figure 8B) and the T1/2 recovery of eIF2 increased by 5.2 seconds, again consistent with a decreased rate of recovery (Figure 8D).

These results highlight that while VWM mutations may have a similar impact on the activity of eIF2B, they show contrasting effects on eIF2B localisation. Currently, VWM pathophysiology is poorly understood largely due to limited correlation between the activity of mutant eIF2B and the severity of disease (33). These data highlight that VWM causing mutations impact upon eIF2B localisation which may be contributing to the pathogenesis of these mutants.

**DISCUSSION**

In this study, we explored the significance of eIF2B body formation in terms of GEF activity and eIF2B regulation. Since the initial identification of eIF2B bodies, several publications have attempted to elucidate the driving factors behind the localisation of eIF2B (24-31). While these studies have highlighted many interesting observations, they have resulted in confounding conclusions. The conflicting reports raise the question of whether eIF2B bodies form under steady-state growth or just under nutrient limiting conditions. We therefore...
considered whether the differences in the methodologies used to visualise eIF2B could be responsible for the observed differences in eIF2B body formation. The conflicting studies were carried out in different yeast strains. Several differences have been identified across these yeast strains particularly in their stress response phenotypes and also within genes that controlling ribosome biosynthesis (44-46). Distinct ribosomal subpopulations that differ in their protein or RNA components are known to differentially control translation and its regulation within the cell (47). We therefore hypothesised that strain differences may impact the formation of eIF2B bodies. In agreement with this, we found variation in the number of cells displaying eIF2B bodies across three different wild-type strains; with two strains harbouring eIF2B bodies in approximately 50% of cells and the third strain presenting with a significantly lower percentage of cells harbouring eIF2B bodies (Figure 1B).

Another consideration for differences observed in eIF2B localisation is whether the tag used to visualise eIF2B could be impacting on its localisation. Here we used a yeast enhanced GFP tag to visualise eIF2B localisation, GFP has a tendency to self-aggregate and therefore we wanted to ensure the eIF2B bodies we observed were not due to GFP aggregation. We individually tagged each of the 5 subunits of eIF2B and calculated the percentage of cells that contained eIF2B bodies. If the GFP tag was responsible for the aggregation of eIF2B into eIF2B bodies we would expect to see the same percentage of cells with eIF2B bodies, regardless of the eIF2B subunit tagged. These experiments revealed that localisation was not uniform across all subunits, suggesting that the eIF2B bodies we have observed are not due to aggregation of the GFP tag (Figure 1A). This is further supported by our previous work where eIF2B bodies were observed using CFP and YFP tags (24) and via immunolocalisation studies using both endogenous and HA-tagged subunits of eIF2B. (24, 25).

Interestingly, cells with GFP tagged eIF2Bα or δ showed a reduced percentage of cells containing eIF2B bodies, compared to the other three eIF2B subunits. This decrease could be due to the position of the tag. The C-terminus of δ is important for heterodimerisation with eIF2Bβ whilst the C-terminus of eIF2Bα is important for homodimerization (48, 49). Analysis of recent eIF2B structures reveals that the interface between eIF2Bα and δ is largely formed from the C-terminus of both subunits (10-13) and analytical centrifugation experiments have demonstrated that eIF2Bα is required to stabilise the eIF2B decamer, with eIF2B(βδεγ) tetramers unable to dimerise in the absence of eIF2Bα homodimers (15). Therefore, it is likely that the addition of the GFP protein tag to the C-terminus of either eIF2Bα or δ subunits would disrupt eIF2B decameric assembly. The decreased percentage of cells harbouring eIF2B bodies suggests that eIF2B decameric assembly may promote the formation of eIF2B bodies. In fitting with this hypothesis, we previously highlighted that the localisation of eIF2B bodies was dispersed in the presence of point mutations in eIF2Bα (26). Here, we have expanded on this and observed that deletion of the α subunit also leads to the complete dispersal of the eIF2B body (Figure 2A). It is therefore likely that the eIF2B decamer must form before eIF2B is able to localise and multimerise to give eIF2B bodies, illustrated in our model of eIF2B body formation presented in Figure 9.

Although eIF2Bα is the only non-essential subunit of eIF2B in yeast, it does play critical roles in the regulation of translation initiation in response to stress (43). The dispersal of eIF2B bodies in the absence of eIF2Bα (Gcn3p) therefore suggests that the localisation of eIF2B may have a regulatory role in translation as a response to cellular stress. This interpretation is consistent with previous work studying the regulation of eIF2B localisation as a response to fusel alcohol stress where a decreased movement of eIF2B bodies within the cell was found to correlate with decreased translation (32). Furthermore, recent studies have suggested that eIF2B bodies form during cellular stress (28,31). Although we observed different numbers of cells with eIF2B bodies in three different wildtype strains during steady state growth, we were able to address the hypothesis that increased eIF2B body formation occurs during stress by
monitoring localisation under acute glucose starvation and the classical eIF2B dependent stress, amino acid starvation (Figure 1B). Although we did not see an increase in the number of cells displaying eIF2B bodies in the absence of glucose, we did see an increase when cells were subjected to amino acid starvation, suggesting that eIF2B dependent stress can enhance the formation of eIF2B bodies.

A number of eIF2Bα mutations that abolish its regulatory function, thus rendering the cell unable to respond to stress, have been well-characterised and are known as Gcn- mutations. These Gcn- mutations produced a phenotype where eIF2B was mostly dispersed throughout the cytoplasm (Figure 4Ai). Interestingly, while these mutations did not impact on the expression level of eIF2Bα (Gcn3p), this phenotype mirrored the phenotype observed from S. cerevisiae lacking the α subunit (gcn3Δ), implying that Gcn- mutations may completely abolish the α subunit from the decameric holocomplex (Figure 9). In mammalian cells eIF2B has been shown to form subcomplexes with reduced GEF activity in the absence of eIF2Bα (8, 29). The formation of these eIF2B subcomplexes has not been investigated in yeast, however yeast expressing these Gcn mutations are viable suggesting active complexes of eIF2B are present within the cells. Crystallographic studies of eIF2B from S. cerevisiae localises Gcn- mutations to the eIF2α-P interface as well as the eIF2Bα-β and the eIF2Bα-δ interfaces (Figure 3), suggesting that stable interactions between the regulatory subunits are required for localisation (Figure 4). This is consistent with recent analysis of the eIF2B cryo-EM structure which indicates eIF2B bodies are formed by polymerisation of intact eIF2B decamers (30). As the decameric conformation of eIF2B is required for eIF2B to recognise and interact with eIF2α-P (23), it is therefore plausible that eIF2B cannot sense stress in the presence of these Gcn- mutants as a result of disruption to eIF2B assembly. Interestingly a series of de novo human eIF2B1 variants have recently been identified in patients presenting with neonatal diabetes (45). Two of these novel eIF2B1 mutations are equivalent residues to the Gcn- residues analysed in this work and they all map to the surface region of eIF2B1 which interacts with phosphorylated eIF2α. This may imply that eIF2B localisation may be an important feature of these regulatory mutations in this disease. Therefore, the Gcn- mutant analysis suggests that the eIF2B bodies are important for regulation.

We were also interested to investigate the importance of eIF2B bodies for eIF2B GEF activity itself. Gcd- mutations, which decrease the catalytic activity of eIF2B, consistently produced a phenotype with multiple eIF2B foci, which we termed microfoci (Figure 4Aii). However, Gcd- mutants still respond to the phosphorylation of eIF2α suggesting that eIF2Bα is still present within eIF2B and hence, the decameric structure is intact when these mutations are present (Figure S2B and Figure 9). Indeed, most of the Gcd- Gcn3p mutations do not seem to directly impede interactions between eIF2Bα and eIF2Bβ/δ (Figure 3). Instead, they are likely to affect the structural integrity of eIF2Bα subunit but it is currently unclear how this would lead to reduced catalytic capacity of eIF2B. Interestingly, microfoci were previously observed when interactions between the very long fatty acids (VLFA) beta-keto-reductase Ifa38p and the catalytic subunits eIF2Bε/γ were abrogated (51). This suggests that other interactions are important for the complete localisation of eIF2B to eIF2B bodies as well as its GEF activity. One exception observed in these studies was the AA 303//305Δ Gcd- mutant, which did not significantly decrease the number of eIF2B bodies formed. Previous studies on this particular mutant highlighted that the loss of 3 amino acids at the extreme C-terminal domain upregulated the overall expression of gcn3 10-fold (40). Gcn3p appears to be integral for the formation of eIF2B bodies. If levels of Gen3p are upregulated in 303//305Δ Gcd- mutant cells, this overexpression of Gcn3p could partially rescue eIF2B body formation, thus cells displaying eIF2B bodies were observed in addition to the classical Gcd- microfoci phenotype.

eIF2Bα VWM mutations were found to have diverse impacts on impact eIF2B body formation (Figure 7B). VWM missense mutations, F240V and N209Y, displayed Gcn- phenotypes, as
determined by polysomal analysis (Figure 7A). N209Y mutant cells displayed a similar dispersed eIF2B localisation phenotype to the Gcn" mutant strains. Biochemical analysis of this conserved mutant in human cells demonstrated the mutant eIF2B complex was less sensitive to inhibition by eIF2α-P (35), supporting a role for eIF2B bodies in the regulation of eIF2B activity. In the F240V mutant, this dispersed phenotype was not observed and instead eIF2B bodies formed, but in a reduced percentage of cells. Interestingly, eIF2 was not found to localise to these eIF2B bodies suggesting they are functionally impaired, perhaps contributing to the cells Gcn" phenotype. For the other VWM mutants, a reporter analysis suggests that the there are no gross deficiencies in the eIF2B GEF activity (Figure S4B), however the V184D mutant harboured an increased percentage of cells with microfoci and the eIF2B bodies present in K111E and Y274C mutant cells displayed a slower rate of eIF2 shuttling implying they have decreased GEF activity.

These data provide key insights into the formation of eIF2B bodies and their importance for eIF2B GEF activity and regulation within the cell. Under normal growth conditions eIF2B bodies exist in a strain-dependent manner, however in the presence of cellular stresses that target eIF2B activity through the phosphorylation of eIF2α, an increase in the percentage of cells harbouring eIF2B bodies occurs independent of strain. These data highlight a regulatory role for eIF2B bodies during cellular stress. This is further highlighted by complete loss of eIF2B bodies in the presence of Gcn" mutations, which abrogate the cells ability to respond to stress induced eIF2αP. In addition to their regulatory role, the formation of eIF2B bodies appears to correlate with enhanced eIF2B catalytic activity. Gcd" mutations, which decrease eIF2B GEF activity, disrupt eIF2B body formation resulting in cells exhibiting multiple smaller eIF2B containing foci termed microfoci. The catalytic activity of these microfoci is reduced when compared to eIF2B bodies. VWM causative point mutations also disrupted patterns of eIF2B localisation, providing the first evidence that eIF2B localisation may be linked to VWM pathophysiology. VWM disease has a wide clinical spectrum and correlations between genotype and phenotype remain elusive. In certain cases, patients suffering the most severe VWM phenotypes harbour eIF2B mutations that biochemical studies have shown to have no impact on eIF2B complex formation or eIF2B activity (34). These data suggest that eIF2B modulation and regulation within eIF2B bodies may be a key facet to understanding the pathophysiology of VWM.

EXPERIMENTAL PROCEDURES

Strains construction and growth conditions
Yeast strain genotypes are displayed in Table I and are derived from the W3031A yeast background strain with the exception of ySC which is derived from BY4741 and yMK1180 which is derived from s288c yeast backgrounds. All strains are auxotrophic for specific amino acids or nucleobases. The strains were typically grown in rich YPD media (1% (w/v) Yeast extract, 2% (w/v) Bacto Peptone and 2% (w/v) glucose) or in minimal synthetic complete media (SCD; 0.17% (w/v) Yeast nitrogen base without amino acids, 0.5% (w/v) ammonium sulphate, 2% (w/v) glucose) at 30°C (52), supplemented with specific dropouts (Formedium) depending on the genotype of the strain. In liquid media, strains were incubated at 30°C with agitation while growth on solid media, YPD or SCD was supplemented with 2% (w/v) agar. Nutrient starvation was performed by the removal of all amino acids for 30 min and carbon source starvation was performed by the removal of glucose for 10 min.

Plasmids used in this study
The plasmids used in this study are Table II. A number of plasmids, denoted pAV, were kindly gifted by Prof. G. Pavitt (The University of Manchester).

Site directed mutagenesis
Site directed mutagenesis was performed using the QuikChange II XL kit (Agilent) as instructed by the manufacturers. Plasmid DNA was isolated from multiple independent transformants and plasmids were Sanger sequenced to confirm the desired mutation had been generated.

Western blot analysis
Protein extracts were generated from yeast cultures grown to an OD600 of 0.6. All cells were lysed and protein samples were prepared, electrophoretically separated, and subjected to immunoblot analysis as described previously (24). Western blotting was carried out as previously described (24) using the following antibodies; eIF2Bα/Gcn3p (a kind gift from Prof. G. Pavitt, The University of Manchester, UK) at 1:500 dilution and Pab1p (a kind gift from Prof. M. Ashe, The University of Manchester, UK) at 1:5000 dilution. Primary antibodies were detected using Goat anti-rabbit IRDye 680RD P/N 925-68071 and Goat anti-mouse IRDye 800CW P/N 925-32210 (Licor) respectively.

**Assays of GCN4-lacZ Reporter Expression**

Standard methods for measuring the β-galactosidase activity for strains bearing GCN4-lacZ fusions were used (53). β-Galactosidase levels are expressed as nanomoles of o-nitrophenol β-D-galactopyranoside hydrolyzed per min/μg of total protein.

**Live-cell imaging and quantification of eIF2B localisation**

Strains were grown at 30 °C until they reached an OD600 of 0.6. Cultures were placed on a 1 % (w/v) poly-L-lysine coated slide (ThermoFisher, UK) and visualised on a Zeiss LSM 510 confocal microscope using a 63 x plan-apochromat oil objective lens. To image GFP, an argon laser (488 nm) was typically used with a maximum output of 25 mW at 55 % laser capacity. Images were analysed either using Zeiss 2009 software or the National Institutes of Health (NIH) ImageJ software. For each strain/mutant analysed, the localisation of eIF2B was assessed for 100 cells per replicate (unless otherwise stated) and 3 independent replicates were performed. Three different localisation patterns were observed for eIF2B. The localisation pattern was defined as an eIF2B body, in cells where one large, commonly filamentous, structure could be observed. In cells where eIF2B localised to multiple smaller punctate foci, these foci were defined as eIF2B microfoci. In cells where no eIF2B foci were visible and instead fluorescence was evenly distributed across the cytoplasm, the localisation phenotype of eIF2B was referred to as dispersed.

**Fluorescent recovery after photobleaching (FRAP)**

FRAP was performed to measure the shuttling of eIF2α-GTP through eIF2B foci as previously described by (24). Cytoplasmic foci were imaged and bleached using the argon laser at full capacity. Following the pre-bleach and bleach steps, the recovery of eIF2B into the cytoplasmic was followed by taking iterative images every 1.8 seconds for 25 cycles. 25 cells were analysed for each replicate.

**Fluorescence recovery was normalised to the total fluorescence of the cell. Background fluorescence was also measured and subtracted from fluorescence recovery. Normalised data was fitted to a one-phase association curve to find mobile eIF2 and half-time recovery. A rate of recovery was calculated from the one-phase association curves by dividing the plateau by the rate constant (k). The eIF2 content of cytoplasmic foci was determined using NIH ImageJ software.**

**Analysis of ribosome distribution on sucrose gradients.**

Yeast cultures were grown to an OD600 of 0.6 and harvested by centrifugation. When cells were subjected to nutritional stress (e.g. amino acid or glucose starvation) cultures were split into two 50 mL cultures, centrifuged and resuspended in media either with or without amino acids or glucose, as described above. Cells were lysed in polyribosomal buffer containing 100 μg/ml cycloheximide and 2.5 OD260 units of extracts were layered onto 15–50% sucrose gradients. The gradients were sedimented via ultracentrifugation at 40,000 rpm using a Th-641 swing-out rotor in a Sorvall WX Ultracentrifuge or 2.5 h. Monosome and polysome peaks were quantified using the National Institutes of Health ImageJ software (http://rsb.info.nih.gov/ij/).

**Statistical analysis**
To determine statistical significance between different groups within each data set, a Shapiro-Wilk test was performed to test for normality. All data presented was considered non-parametric and therefore, individual groups were compared to each other using the Kruskal-Wallis test followed by a Conover Inman posthoc test.

**Structural analysis of eIF2Bα mutations**

PyMOL was used to produce eIF2B structural representations using crystal structure data derived from *S.cerevisiae*, PDB ID: 6i3m and 6i7t (10). The structure of the eIF2B complex is shown in ribbon representation with individual subunits coloured and labelled. The eIF2Bα homodimer is shown in surface representation with residues residing within the interface between the eIF2Bα subunits and either eIF2B subunits or the alpha subunit of eIF2 are colour coded. eIF2Bα mutant residues were identified and labelled with proximal residues from other eIF2B subunits also labelled for visual representation.
All data are included within the manuscript

Acknowledgments
We would like to thank Prof Graham Pavitt for the kind gift of plasmids and antibodies.

Funding information
KN was funded through a PhD studentship awarded by the Biomedical Sciences Research Centre, Sheffield Hallam University. RH is funded by a GOSH/Sparks charity award V4119.

Conflict of interest
The authors declare that they have no conflicts of interest with the contents of this article.

REFERENCES

1. Merrick, W. C., and Pavitt, G. D. (2018) Protein Synthesis Initiation in Eukaryotic Cells. Cold Spring Harb Perspect Biol 10(12):a033092.
2. Huang, H. K., Yoon, H., Hannig, E. M., and Donahue, T. F. (1997) GTP hydrolysis controls stringent selection of the AUG start codon during translation initiation in Saccharomyces cerevisiae. Genes Dev 11, 2396-2413.
3. Erickson, F. L., and Hannig, E. M. (1996) Ligand interactions with eukaryotic translation initiation factor 2: role of the gamma-subunit. EMBO J 15, 6311-6320.
4. Pavitt GD. Regulation of translation initiation factor eIF2B at the hub of the integrated stress response. Wiley Interdiscip Rev RNA. 2018 Nov;9(6):e1491.
5. Jennings, M. D., and Pavitt, G. D. (2010) eIF5 has GDI activity necessary for translational control by eIF2 phosphorylation. Nature 465, 378-381.
6. Jennings, M. D., Zhou, Y., Mohammad-Qureshi, S. S., Bennett, D., and Pavitt, G. D. (2013) eIF2B promotes eIF5 dissociation from eIF2*GDP to facilitate guanine nucleotide exchange for translation initiation. Genes Dev 27, 2696-2707.
7. Gordiyenko, Y., Schmidt, C., Jennings, M. D., Matak-Vinkovic, D., Pavitt, G. D., and Robinson, C. V. (2014) eIF2B is a decameric guanine nucleotide exchange factor with a γ2 ε2 tetrameric core. Nat Commun 5, 3902.
8. Wortham, N. C., Martinez, M., Gordiyenko, Y., Robinson, C. V., and Proud, C. G. (2014) Analysis of the subunit organization of the eIF2B complex reveals new insights into its structure and regulation. FASEB J 28, 2225-2237.
9. Kashiwagi, K., Takahashi, M., Nishimoto, M., Hiyama, T. B., Higo, T., Umehara, T., Sakamoto, K., Ito, T., and Yokoyama, S. (2016) Crystal structure of eukaryotic translation initiation factor 2B. Nature 531, 122-125.
10. Adomavicius, T., Guaita, M., Zhou, Y., Jennings, M. D., Latif, Z., Roseman, A. M. and Pavitt, G. D. (2019). The structural basis of translational control by eIF2 phosphorylation. Nat. Commun. 10, 2136.
11. Gordiyenko, Y., Llácer, J. L., and Ramakrishnan, V. (2019). Structural basis for the inhibition of translation through eIF2 phosphorylation. Nat. Commun 10, 2640.
12. Kashiwagi, K., Yokoyama, T., Nishimoto, M., Takahashi, M., Sakamoto, A., Yonemochi, M., Shirouzu, M. and Ito, T. (2019). Structural basis for eIF2B inhibition in integrated stress response. Science 364, 495–499.
13. Kenner, L. R., Anand, A. A., Nguyen, H. C., Myasnikov, A. G., Klose, C. J., McGeever, L. A., Tsai, J. C., Miller-Vedam, L. E., Walter, P. and Frost, A. (2019). eIF2B-catalyzed nucleotide exchange and phosphoregulation by the integrated stress response. Science 364, 491–495.
14. Wortham, N. C., Stewart, J. D., Harris, S., Coldwell, M. J., and Proud, C. G. (2016) Stoichiometry of the eIF2B complex is maintained by mutual stabilization of subunits. Biochem J 473, 571-580.
Tsai, J. C., Miller-Vedam, L. E., Anand, A. A., Jaishankar, P., Nguyen, H. C., Renslo, A. R., Frost, A. and Walter, P. (2018). Structure of the nucleotide exchange factor eIF2B reveals mechanism of memory-enhancing molecule. Science 359, eaq9399.

Harding, H. P., Zhang, Y., Bertolotti, A., Zeng, H., and Ron, D. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 5, 897-904.

Dever, T. E., Feng, L., Wek, R. C., Cigan, A. M., Donahue, T. F., and Hinnebusch, A. G. (1992) Phosphorylation of initiation factor 2 alpha by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell 68, 585-596.

Pakos-Zebrucka K, Koryga I, Mnich K, Ljujić M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016 Oct;17(10):1374-1395.

Baird, T. D., & Wek, R. C. (2012). Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism. Advances in Nutrition, 3(3), 307–321.

Pavitt, G. D., Yang, W. and Hinnebusch, A. G. (1997). Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2. Mol. Cell. Biol. 17, 1298–1313.

Pavitt GD, Ramaiah KV, Kimball SR, Hinnebusch AG. eIF2 independently binds two distinct eIF2B subcomplexes that catalyze and regulate guanine-nucleotide exchange. Genes Dev. 1998 Feb 15;12(4):514-26.

Mueller PP, Hinnebusch AG. Multiple upstream AUG codons mediate translational control of GCN4. Cell. 1986 Apr 25;45(2):201-7.

Bogorad, A. M., Lin, K. Y., and Marintchev, A. (2017) Novel mechanisms of eIF2B action and regulation by eIF2alpha phosphorylation. Nucleic Acids Res 45, 11962-11979.

Campbell, S. G., Hoyle, N. P., and Ashe, M. P. (2005) Dynamic cycling of eIF2 through a large eIF2B-containing cytoplasmic body: implications for translation control. J Cell Biol 170, 925-934.

Noree, C., Sato, B. K., Broyer, R.M., Wilhelm, J. E. (2010) Identification of novel filament-forming proteins in Saccharomyces cerevisiae and Drosophila melanogaster. J Cell Biol 190 (4): 541–551.

Taylor, E. J., Campbell, S. G., Griffiths, C. D., Reid, P. J., Slaven, J. W., Harrison, R. J., Sims, P. F., Pavitt, G. D., Delneri, D., and Ashe, M. P. (2010) Fusel alcohols regulate translation initiation by inhibiting eIF2B to reduce ternary complex in a mechanism that may involve altering the integrity and dynamics of the eIF2B body. Mol Biol Cell 21, 2202-2216.

Egbe, N. E., Paget, C. M., Wang, H., and Ashe, M. P. (2015) Alcohols inhibit translation to regulate morphogenesis in C. albicans. Fungal Genet Biol 77, 50-60.

Moon, S. L., and Parker, R. (2018) Analysis of eIF2B bodies and their relationships with stress granules and P-bodies. Sci Rep 8, 12264.24.

Hodgson, R. E., Varanda, B. A., Ashe, M. P., Allen, K. E., and Campbell, S. G. (2019) Cellular eIF2B subunit localization: implications for the integrated stress response and its control by small molecule drugs. Mol Biol Cell 30, 942-958.

Marini, G., Nüske, E., Leng, W., Alberti, Sand Pigino, G. (2020) Reorganization of budding yeast cytoplasm upon energy depletion. Mol Biol Cell 31(12):1232-1245.

Nüske E, Marini G, Richter D, Leng W, Bogdanova A, Franzmann TM, Pigino G, Alberti S. Filament formation by the translation factor eIF2B regulates protein synthesis in starved cells. Biol Open. 2020 Jul 8;9(7):bio046391.

Leegwater, P. A. J., Vermeulen, G., Konst, A. A. M., Naidu, S., Mulders, J., Visser, A., Kersbergen, P., Mobach, D., Fonds, D., van Berkel, C. G. M., Lemmers, R. J. L. F., Frants, R. R., Oudejans, C. B. M., Schutgens, R. B. H., Pronk, J. C., and van der Knaap, M. S. (2001) Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 29, 383-388.

Hamilton E. M. C, van der Lei H. D. W., Vermeulen G., Gerver J. A. M., Lourenço C. M., Naidu S., Mierzweska H., Gemke R. J. B. J., de Vet H. C. W., Uitdehaag B. M. J., et al (2018). Natural history of vanishing white matter. Ann Neurol, 24–288.
34. Liu R., van der Lei H. D. W., Wang X., Wortham N. C., Tang H., van Berkel C. G. M., Mufunde T. A., Huang W., van der Knaap M. S., Scheper G. C., et al (2011). Severity of vanishing white matter disease does not correlate with deficits in eIF2B activity or the integrity of eIF2B complexes. Hum Mutat. 32: 1036–1045.

35. Wortham, N. C. and Proud, C. G. (2015). Biochemical effects of mutations in the gene encoding the alpha subunit of eukaryotic initiation factor (eIF) 2B associated with Vanishing White Matter disease. BMC Med Genet, 16, 64.

36. Petrezselyova, S., Zahradka, J., and Sychrova, H. (2010) Saccharomyces cerevisiae BY4741 and W303-1A laboratory strains differ in salt tolerance. Fungal Biol 114, 144-150.

37. Ashe MP, De Long SK, Sachs AB. (2000) Glucose depletion rapidly inhibits translation initiation in yeast. Mol Biol Cell. 11(3):833-848.

38. Castelli, L. M., Lui, J., Campbell, S., Rowe, W., Zeef, L. A., Holmes, L. E., Hoyle, N. P., Bone, J., Selley, J. N., Sims, P. F. and Ashe, M. P. (2011). Glucose depletion inhibits translation initiation via eIF4A loss and subsequent 48S pre-initiation complex accumulation, while the pentose phosphate pathway is co-ordinately up-regulated. Mol Biol Cell, 22 (18), 3379-3393.

39. Bresson, S., Shchepachev, V., Spanos, C., Turowski, T., Rappsilber, J., and Tolliver, D. (2020) Stress-induced translation inhibition through rapid displacement of scanning initiation factors. Molecular Cell 80, 470–484.

40. Hannig, E. M., Williams, N. P., Wek, R. C., and Hinnebusch, A. G. (1990) The translational activator GCN3 functions downstream from GCN1 and GCN2 in the regulatory pathway that couples GCN4 expression to amino acid availability in Saccharomyces cerevisiae. Genetics 126, 549-562

41. Zhang, H., Dai, L., Chen, N., Zang, L., Leng, X., Du, L., Wang, J., Jiang, Y., Zhang, F., Wu, X., and Wu, Y. (2015) Fifteen novel eIF2B1-5 mutations identified in Chinese children with leukoencephalopathy with vanishing white matter and a long term follow-up. PLoS One 10, e0118001

42. Yoshikawa, K., Tanaka, T., Ida, Y., Furusawa, C., Hirasawa, T., and Shimizu, H. (2011) Comprehensive phenotypic analysis of single-gene deletion and overexpression strains of Saccharomyces cerevisiae. Yeast 28, 349-361.

43. Richardson, J. P., Mohammad, S. S., and Pavitt, G. D. (2004) Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity. Mol Cell Biol 24, 2352-2363.

44. Ralser M., Kuhl H., Ralser M., Werber M., Lehrach H., Breitenbach M. and Timmermann B. (2012). The Saccharomyces cerevisiae W303-K6001 cross-platform genome sequence: insights into ancestry and physiology of a laboratory mutt. Open Biol 2(8), 120093.

45. Matheson K, Parsons L, Gammie A. Whole-Genome Sequence and Variant Analysis of W303, a Widely-Used Strain of Saccharomyces cerevisiae. G3 (Bethesda). 2017 Jul 5;7(7):2219-2226.

46. Schacherer J, Ruderfer DM, Gresham D, Dolinski K, Botstein D, et al. (2007) Genome-Wide Analysis of Nucleotide-Level Variation in Commonly Used Saccharomyces cerevisiae Strains. PLOS ONE 2(3): e322.

47. Sauert M, Temmel H, Moll I. Heterogeneity of the translational machinery: Variations on a common theme. Biochimie. 2015 Jul;114:39-47.

48. Bogorad, A. M., Xia, B., Sandor, D. G., Mamonov, A. B., Cafarella, T. R., Jehle, S., Vajda, S., Kozakov, D. and Marintchev, A. (2014). Insights into the Architecture of the eIF2Bα/β/δ Regulatory Subcomplex. Biochemistry 21, 3432-3445.

49. Wang, X., Wortham, N. C., Liu, R. and Proud, C. G. (2012). Identification of Residues That Underpin Interactions within the Eukaryotic Initiation Factor (eIF2) 2B Complex. J. Biol. Chem. 287, 8263–8274.

50. De Franco E., Caswell R., Johnson M.B., et al. (2020)De Novo Mutations in EIF2B1 Affecting eIF2 Signaling Cause Neonatal/Early-Onset Diabetes and Transient Hepatic Dysfunction. Diabetes. 69(3):477-483.
51. Browne, C. M., Samir, P., Fites, J. S., Villarreal, S. A. and Link, A. J. (2013). The yeast eukaryotic translation initiation factor 2B translation initiation complex interacts with the fatty acid synthesis enzyme YBR159W and endoplasmic reticulum membranes. Mol Cell Biol, 33, 1041-56.

52. Guthrie, C. and Fink, R. F. (1991). Guide to yeast genetics and molecular biology. Methods Enzymol.194, 9-993.

53. Lucchini, G., Hinnebusch, A. G., Chen, C. and Fink, G. R. (1984). Positive regulatory interactions of the HIS4 gene of Saccharomyces cerevisiae. Mol. Cell. Biol. 4, 1326-1333.
| Strain   | Genotype                                                                 | Source               |
|----------|---------------------------------------------------------------------------|----------------------|
| yMK880   | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418 | (24)                 |
| yMK883   | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180, SUI2-yeGFP::G418 | (24)                 |
| yMK1402  | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2 | (25)                 |
| ySC37    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3 URA3 2μ] | This study           |
| ySC38    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-T41A URA3 2μ] | This study           |
| ySC39    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E44V URA3 2μ] | This study           |
| ySC40    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E44K URA3 2μ] | This study           |
| ySC41    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F73L URA3 2μ] | This study           |
| ySC42    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-N80D URA3 2μ] | This study           |
| ySC43    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F240I URA3 2μ] | This study           |
| ySC44    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-T291P URA3 2μ] | This study           |
| ySC45    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-S293P URA3 2μ] | This study           |
| ySC46    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3 URA3 CEN] | This study           |
| ySC47    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-A25V, A26V URA3 CEN] | This study           |
| ySC48    | **Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100,** GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-A26T URA3 CEN] | This study           |
| Strain  | Genotype Details                                                                 | Comment |
|---------|----------------------------------------------------------------------------------|---------|
| ySC49   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-R104K URA3 CEN]* | This study |
| ySC50   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-V295F URA3 CEN]* | This study |
| ySC51   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-D71N URA3 CEN]* | This study |
| ySC52   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-E199K URA3 CEN]* | This study |
| ySC53   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-AA303-305Δ URA3 CEN]* | This study |
| ySC54   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-K111E URA3 CEN4ARS6]* | This study |
| ySC55   | *Mata, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-N209Y URA3 CEN4ARS6]* | This study |
| ySC56   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-V184D URA3 CEN4ARS6]* | This study |
| ySC57   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-N209Y URA3 CEN4ARS6]* | This study |
| ySC58   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-F240V URA3 CEN4ARS6]* | This study |
| ySC59   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, gcn3::LEU2, p[GCN3-Y274C URA3 CEN4ARS6]* | This study |
| ySC61   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180, SUI2-GFP::G418, gcn3::LEU2* | This study |
| ySC62   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-A25V,A26V URA3 CEN]* | This study |
| ySC67   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-E199K URA3 CEN]* | This study |
| ySC68   | *Mat a, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180, SUI2-GFP::G418, gcn3::LEU2, p[GCN3-AA303-305Δ URA3 CEN]* | This study |
| Name   | Genotype                                                                 | Source     |
|--------|---------------------------------------------------------------------------|------------|
| ySC9   | MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 GCD1-yeGFP::HygR                          | This study |
| yMK180 | MATa leu2-3, 112, ura3-52::[HIS4-lacZ ura3-52] ino1, gcd6Δ, gen2A::hisG, GCD1-yeGFP::G418, p[GCD6 CEN6 LEU2] |            |
| ySC91  | Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 p[gcn3 K111E URA3 CEN6ARS4] | This study |
| ySC92  | Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 p[gcn3 V184D URA3 CEN6ARS4] | This study |
| ySC93  | Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 p[gcn3 N209Y URA3 CEN6ARS4] | This study |
| ySC94  | Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 p[gcn3 F240V URA3 CEN6ARS4] | This study |
| ySC95  | Mat α, ADE2, his3-11,15, leu2-3,112, trp1-1, ura3-1, can1-100, GCD1-P180-yeGFP::G418, GCN4-LacZ-TRP1, gcn3::HIS3 p[gcn3 Y274C URA3 CEN6ARS4] | This study |

Table II. Plasmids used within this study

Name | Genotype | Source   
--- | --- | --- |
| pSC116 | p[GCN3 K111E URA3 CEN6ARS4] | This study |
| pSC117 | p[GCN3 V184D URA3 CEN6ARS4] | This study |
| pSC118 | p[GCN3 F240V URA3 CEN6ARS4] | This study |
| pSC119 | p[GCN3 Y274C URA3 CEN6ARS4] | This study |
| pAV1108 | p[GCN3(T41A) URA3 2μ] | (40) |
| pAV1109 | p[GCN3(E44V)URA3 2μ] | (40) |
| pAV1110 | p[GCN3(E44K)URA3 2μ] | (40) |
| pAV1111 | p[GCN3(F73L) URA3 2μ] | (40) |
| pAV1112 | p[GCN3(N80D) URA3 2μ] | (40) |
| pAV1113 | p[GCN3(F240I) URA3 2μ] | (40) |
| pAV1115 | p[GCN3 (T291P) URA3 2μ] | (40) |
| pAV1116 | p[GCN3 (S293R) URA3 2μ] | (40) |
| pAV1117 | p[GCN3 URA3 2μ] | (40) |
| pAV1170 | p[GCN3 URA3 CEN] | (40) |
| pAV1239 | p[GCN3(AA2526VV) URA3 CEN] | (40) |
| pAV1240 | p[GCN3(A26T) URA3 CEN] | (40) |
| pAV1241 | p[GCN3(R104K) URA3 CEN] | (40) |
| pAV1242 | p[GCN3(V295F) URA3 CEN] | (40) |
| pAV1243 | p[GCN3(D71N) URA3 CEN] | (40) |
| pAV1244 | p[GCN3(E199K) URA3 CEN] | (40) |
| pAV1268 | p[GCN3(303//305Δ) URA3 CEN] | (40) |
| pAV1729 | p[GCN4 leader-lacZ-TRP1] | (40) |
| pAV1769 | p[GCN3 URA3 CEN6 ARS4] | (43) |
| pAV1778 | p[GCN3(N209Y) URA3 CEN6 ARS4] | (43) |
Figure 1 – The percentage of cells containing eIF2B bodies differs depending on the subunit C-terminally tagged and the lab strain of *S. cerevisiae*. (A) Each eIF2B subunit was individually C-terminally GFP-tagged in the W303-1A background strain. The number of cells displaying eIF2B bodies was analysed and presented as a percentage of total cells counted, a minimum of 50 cells were counted for each experiment, n=3. (B) *GCD1* (eIF2Bγ) was C-terminally GFP-tagged in the *S. cerevisiae* background strains W303-1A (yMK880), BY4741 (ySC9) and S288c (yMK1180). Following logarithmic growth, each strain was subjected to amino acid and glucose starvation for 30 minutes, before eIF2B localisation was assessed. The number of cells displaying eIF2B bodies was analysed and presented as a % of total cells counted, a minimum of 50 cells were counted for each experiment, n=3 . ns = not significant, **** p=<0.0001.
Figure 2 – eIF2Bα is required for eIF2B body formation. (A) Confocal microscopy of GCD1-yeGFP (yMK880), SUI2-yeGFP (yMK883), GCD1-yeGFP gcn3::LEU2 (yMK1402) and SUI2-yeGFP gcn3::LEU2 (ySC16). Null strains were transformed with a low copy Cen plasmid (pAV1170) or a high copy 2μ plasmid (pAV1117) containing WT GCN3. (B) A minimum of 100 cells were counted and assessed as to whether eIF2B bodies were present, dispersed or localised to microfoci. Overnight cultures were diluted in SCD media to 0.2 OD$_{600}$ and incubated at 30°C with shaking until exponential growth was reached. n=3. Error bars are representative of SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.
Figure 3 – Structural schematic highlighting eIF2Bα mutations. A) The crystal structure solved for *S. cerevisiae* eIF2B is shown in ribbon representation. B) The eIF2B homodimer has been enlarged and is shown as a surface representation with interfaces between eIF2Bα and the other eIF2B/eIF2 subunits colour coded. The position of the amino acid mutations introduced in this study are highlighted. These mutants where modelled on the crystal structure data and are stick representations are shown with amino acids from neighbouring eIF2B/eIF2 subunits highlighted. Gcn− mutants are shown in purple and Gcd− mutants in turquoise. These mutations were expressed in the yMK1402 background strain. (Gcn− mutants PDB ID: 6i3m, Gcd− mutants PDB ID: 6i7t).
Figure 4 – eIF2Ba mutants alter the localisation of eIF2B bodies (A) Cells were grown to log phase and confocal microscopy was used to image the strain yMK1402 (GCD1-yeGFP gcn3::LEU2) containing a series of (i) Gcn- mutants [pAV1108–13, 15 and 16] and (ii) Gcd- mutants [pAV1238-44 and 68]. (B) Cells from each strain were counted to assess whether eIF2B bodies were present, dispersed or localised to microfoci The first part of the graph corresponds to the gcn- mutants and the second part shows the gcd- mutants For each strain analysed the localisation of eIF2B was assessed for 100 cells per biological replicate, n=3. Error bars are representative of SD. ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.
Figure 5 – FRAP analysis of gcn3 Gcd- mutations reveal slower shuttling of eIF2 through eIF2B microfoci. A) Schematic representation of FRAP technique. The eIF2B body/microbody is bleached and the intensity of fluorescent signal within this region is measured, normalised against intensity of the pre-bleached signal and plotted against time. Mobile eIF2 is calculated as the plateau of the FRAP curve. $t_1/2$ Recovery is calculated as the fluorescence measured at the halftime point of total recovery. The rate or recovery is calculated by dividing the plateau value by the rate constant ($k$). B) Three gcn3 Gcd-mutations AA25,26VV (pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)) as well as the GCN3 Cen plasmid (pAV1170) were exogenously expressed in SUI2-yeGFP gcn3::LEU2 (ySC16) to measure eIF2 recovery within eIF2B bodies. Both eIF2B body and microfoci were analysed for the 303//305Δ mutant. (B) Normalised FRAP recovery curves Gcd-mutations AA25,26VV (pAV1239), E199K (pAV1244) and 303//305Δ (pAV1268)) as well as the GCN3 Cen plasmid (pAV1170) were exogenously expressed in SUI2-yeGFP gcn3::LEU2 (ySC16) C) (i) Bar chart representing the mobile eIF2 within the foci as a percentage. (ii) Bar chart representative of half the time needed for eIF2 to fully recover. (iii) Bar chart depicting the rate of eIF2 recovery. Data are representative of 25 cells, n=3, error bars are representative of SD, ns = not significant, * $P<0.05$, ** $P<0.01$, *** $P<0.001$, **** $P<0.0001$. 
### Table

| DNA      | Protein   | Disease Severity       | Zygosity                  | Yeast Conservation | Reference               |
|----------|-----------|------------------------|---------------------------|--------------------|-------------------------|
| c.328A>G | p.Lys110Glu | Classical              | Homozygous               | p.Lys111           | Zhang et al., (2015)    |
| c.574G>T | p.Val183Phe | Juvenile / Adult       | Homozygous               | p.Val184           | Ohlenbusch et al., (2005) |
| c.622A>T | p.Asn208>Tyr | Heterozygous with IVS2+1G>A | p.Asn209                  |                    | Van der Knaap et al., (2002) |
| c.715T>G | p.Phe239Val | Juvenile / Adult       | Homozygous               | p.Phe240           | Shimada et al., (2015)  |
| c.824A>G | p.Tyr275Cys | N/R                    | Heterozygous with Gly204Δ | p.Tyr274           | Maletkovic et al., (2008) |

**Figure 6** – Structural schematic highlighting eIF2Bα VWM mutations. A) The crystal structure solved for *S. cerevisiae* eIF2B is shown on the left in surface representation. B) On the right the eIF2B homodimer has been enlarged and is shown as a surface representation with interfaces between eIF2Bα and the other eIF2B subunits colour coded. The position of the amino acid mutations introduced in this study are highlighted. These mutants where modelled on the crystal structure data and are shown in orange as stick representations, with amino acids from neighbouring eIF2B subunits highlighted. C) The VWM disease severity, zygosity and yeast conservation of these mutations is outlined. These mutations were expressed in the ySC16 background strain. (PDB ID: 6i7t)
Figure 7 – eIF2B localisation in the presence of gcn3 containing VWM missense mutations. (A) Polysome analysis of the strain yMK1402 (GCD1-yeGFP gcn3::LEU2) expressing gcn3 VWM mutants and the low copy WT GCN3 plasmid (ySC91-96. Polysome analysis was as described in Materials and Methods. Polysome/monosome ratios were calculated from measuring the area under the polysome peaks and dividing by the monosome peak area. (B) (i) Cells were grown to log phase and confocal microscopy was used to image the strain yMK1402 (GCD1-yeGFP gcn3::LEU2) expressing gcn3 VWM mutants, Gcn3pK111E (p[GCN3 K111E URA3 CEN6ARS4]), Gcn3pV184D (p[GCN3 V184D URA3 CEN6ARS4]), Gcn3pN209Y (p[GCN3 N209Y URA3 CEN6ARS4]), and the low copy WT plasmid p[GCN3 URA3 CEN6ARS4]). Gcn3pF240V (p[GCN3 F240V URA3 CEN6ARS4]), Gcn3pY274C (p[GCN3 Y274C URA3 CEN6ARS4]) and the low copy WT plasmid p[GCN3 URA3 CEN6ARS4]). (ii) Cells from each strain were counted to assess whether eIF2B bodies were present, dispersed or localised to microfoci. For each strain analysed the localisation of eIF2B was assessed for 100 cells per replicate, n=3. Error bars are representative of SD. Ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.
Figure 8 – FRAP analysis of eIF2 cycling through eIF2B foci in the presence of VWM gcn3 mutations reveal an increase in eIF2 recovery at a slower rate. i) Normalised FRAP recovery curves for the strain ySC16 (SU12-yeGFP gcn3::LEU2) expressing the VWM mutants Gcn3pK11E (p[GCN3 K11E URA3 CEN6ARS4]), Gcn3pY274C (p[GCN3 Y274C URA3 CEN6ARS4]) and the low copy WT plasmid p[GCN3 URA3 CEN6 ARS4] (ii) Bar chart representing the percentage mobile eIF2 within the foci for each mutant. (iii) Bar chart representing the T1/2 needed for eIF2 to fully recover. (iv) Bar chart depicting the rate of eIF2 recovery. Data are representative of 25 cells per replicate, n=3, error bars are representative of SD, ns = not significant, * P=<0.05, ** P=<0.01, *** P=<0.001, **** P=<0.0001.
Figure 9 - Schematic of the relationship between the localisation phenotype of eIF2B and its structure, activity and regulation. In yeast eIF2B displays 3 distinct localisation phenotypes: dispersed eIF2B, eIF2B bodies or eIF2B microfoci. In its active, decameric form, eIF2B localises to eIF2B bodies. In the absence of eIF2Bα, this localisation is lost and a dispersed eIF2B localisation phenotype is observed. eIF2B cannot for an octameric complex in the absence of eIF2Bα and thus we hypothesise eIF2B tetrameric and heterodimeric subcomplexs form. The dispersed eIF2B phenotype is mimicked by Gcn- mutants suggesting a regulatory role for the eIF2B body. Additionally, the localisation of eIF2B to eIF2B bodies appears to enhance eIF2B GEF. Gcd- mutants which decarease GEF activity disrupt eIF2B body localisation and result in an eIF2B microfoci localisation phenotype. The eIF2B microfoci have a decreased interaction with eIF2 and thus appear to have decreased eIF2B GEF activity.